| Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised … B Seddon, SJ Strauss, J Whelan, M Leahy, PJ Woll, F Cowie, ... The lancet oncology 18 (10), 1397-1410, 2017 | 456 | 2017 |
| Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial IS Mackenzie, I Ford, G Nuki, J Hallas, CJ Hawkey, J Webster, SH Ralston, ... The Lancet 396 (10264), 1745-1757, 2020 | 320 | 2020 |
| Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide J Bray, J Sludden, MJ Griffin, M Cole, M Verrill, D Jamieson, AV Boddy British journal of cancer 102 (6), 1003-1009, 2010 | 208 | 2010 |
| Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers … Y Drew, J Ledermann, G Hall, D Rea, R Glasspool, M Highley, G Jayson, ... British journal of cancer 114 (7), 723-730, 2016 | 192 | 2016 |
| Imagestream detection and characterisation of circulating tumour cells–A liquid biopsy for hepatocellular carcinoma? LF Ogle, JG Orr, CE Willoughby, C Hutton, S McPherson, R Plummer, ... Journal of hepatology 65 (2), 305-313, 2016 | 131 | 2016 |
| Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation SC Weatherhead, PM Farr, D Jamieson, JS Hallinan, JJ Lloyd, A Wipat, ... Journal of Investigative Dermatology 131 (9), 1916-1926, 2011 | 126 | 2011 |
| Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? J Margetts, LF Ogle, SL Chan, AWH Chan, KC Chan, D Jamieson, ... British journal of cancer 118 (2), 248-257, 2018 | 88 | 2018 |
| Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma GJ Veal, M Cole, G Chinnaswamy, J Sludden, D Jamieson, J Errington, ... European Journal of Cancer 55, 56-64, 2016 | 68 | 2016 |
| Label‐free leukemia monitoring by computer vision M Doan, M Case, D Masic, H Hennig, C McQuin, J Caicedo, S Singh, ... Cytometry Part A 97 (4), 407-414, 2020 | 57 | 2020 |
| High‐resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers BM Dent, LF Ogle, RL O'Donnell, N Hayes, U Malik, NJ Curtin, AV Boddy, ... International journal of cancer 138 (1), 206-216, 2016 | 56 | 2016 |
| NAD (P) H: quinone oxidoreductase 1 and nrh: quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH: quinone oxidoreductase 2 activity … D Jamieson, K Wilson, S Pridgeon, JP Margetts, RJ Edmondson, ... Clinical cancer research 13 (5), 1584-1590, 2007 | 53 | 2007 |
| Condensin II mutation causes T-cell lymphoma through tissue-specific genome instability J Woodward, GC Taylor, DC Soares, S Boyle, D Sie, K Chathoth, ... Genes & development 30 (19), 2173-2186, 2016 | 51 | 2016 |
| Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase SE Fordham, HJ Blair, CJ Elstob, R Plummer, Y Drew, NJ Curtin, ... Blood advances 2 (10), 1157-1169, 2018 | 48 | 2018 |
| Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo CR Hill, D Jamieson, HD Thomas, CDA Brown, AV Boddy, GJ Veal Biochemical pharmacology 85 (1), 29-37, 2013 | 47 | 2013 |
| Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy D Jamieson, N Cresti, J Bray, J Sludden, MJ Griffin, NM Hawsawi, ... Pharmacogenetics and genomics 21 (12), 808-819, 2011 | 47 | 2011 |
| Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil D Jamieson, J Lee, N Cresti, R Jackson, M Griffin, J Sludden, M Verrill, ... Cancer chemotherapy and pharmacology 74, 667-674, 2014 | 41 | 2014 |
| Pharmacogenetics of genes across the doxorubicin pathway D Jamieson, AV Boddy Expert opinion on drug metabolism & toxicology 7 (10), 1201-1210, 2011 | 38 | 2011 |
| Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma D Jamieson, N Cresti, MW Verrill, AV Boddy Journal of immunological methods 345 (1-2), 106-111, 2009 | 35 | 2009 |
| Detection of circulating and disseminated neuroblastoma cells using the ImageStream flow cytometer for use as predictive and pharmacodynamic biomarkers S Merugu, L Chen, E Gavens, H Gabra, M Brougham, G Makin, A Ng, ... Clinical Cancer Research 26 (1), 122-134, 2020 | 33 | 2020 |
| Reduction of mitomycin C is catalysed by human recombinant NRH: quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor D Jamieson, ATY Tung, RJ Knox, AV Boddy British journal of cancer 95 (9), 1229-1233, 2006 | 33 | 2006 |